Movement Alert｜Illumina Rises 5.09% in Regular Trading, Launches Whole-Genome Cancer Residual Disease Detection Workflow

Market Focus05-29

On May 29, Illumina rose 5.09% in regular trading, trading at $157.87/share, with trading volume of $142 million. The move was driven by the company's announcement of its first distributed whole-genome sequencing solution for high-sensitivity molecular residual disease (MRD) research.

The new workflow is designed to support residual disease detection and cancer genomic profiling using solid tumor and blood samples. According to the company, the workflow completes processing in approximately five days and targets analytical sensitivity down to 10 parts per million for certain tumors. Illumina's Dragen analysis software links tumor profiles with circulating tumor DNA data and achieved 99.5% analytical specificity in testing designed to distinguish tumor signals from background noise. The company has opened early access to select clinical research partners and plans a broader commercial launch next year.

The broader Life Sciences Tools & Services sector also posted strong gains, with Agilent up 18.83%, Icon PLC up 14.86%, Tempus AI up 8.54%, Thermo Fisher Scientific up 6.69%, and Danaher up 3.97%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1197222612?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-29 01:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197222612","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Illumina Rises 5.09% in Regular Trading, Launches Whole-Genome Cancer Residual Disease Detection Workflow","media":"Market Focus","content":"<p><p>On May 29, Illumina rose 5.09% in regular trading, trading at $157.87/share, with trading volume of $142 million. The move was driven by the company's announcement of its first distributed whole-genome sequencing solution for high-sensitivity molecular residual disease (MRD) research.</p><p>The new workflow is designed to support residual disease detection and cancer genomic profiling using solid tumor and blood samples. According to the company, the workflow completes processing in approximately five days and targets analytical sensitivity down to 10 parts per million for certain tumors. Illumina's Dragen analysis software links tumor profiles with circulating tumor DNA data and achieved 99.5% analytical specificity in testing designed to distinguish tumor signals from background noise. The company has opened early access to select clinical research partners and plans a broader commercial launch next year.</p><p>The broader Life Sciences Tools & Services sector also posted strong gains, with Agilent up 18.83%, Icon PLC up 14.86%, Tempus AI up 8.54%, Thermo Fisher Scientific up 6.69%, and Danaher up 3.97%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Illumina Rises 5.09% in Regular Trading, Launches Whole-Genome Cancer Residual Disease Detection Workflow</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Illumina Rises 5.09% in Regular Trading, Launches Whole-Genome Cancer Residual Disease Detection Workflow\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-29 01:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 29, Illumina rose 5.09% in regular trading, trading at $157.87/share, with trading volume of $142 million. The move was driven by the company's announcement of its first distributed whole-genome sequencing solution for high-sensitivity molecular residual disease (MRD) research.</p><p>The new workflow is designed to support residual disease detection and cancer genomic profiling using solid tumor and blood samples. According to the company, the workflow completes processing in approximately five days and targets analytical sensitivity down to 10 parts per million for certain tumors. Illumina's Dragen analysis software links tumor profiles with circulating tumor DNA data and achieved 99.5% analytical specificity in testing designed to distinguish tumor signals from background noise. The company has opened early access to select clinical research partners and plans a broader commercial launch next year.</p><p>The broader Life Sciences Tools & Services sector also posted strong gains, with Agilent up 18.83%, Icon PLC up 14.86%, Tempus AI up 8.54%, Thermo Fisher Scientific up 6.69%, and Danaher up 3.97%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ILMN","symbol_name":"Illumina","start_time":0,"source_url":"","article_id":"1197222612","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197222612","pubTimestamp":1779989976,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 29, Illumina rose 5.09% in regular trading, trading at $157.87/share, with trading volume of $142 million. The move was driven by the company's announcement of its first distributed...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ILMN":"Illumina"},"translate_title":"动静提示|Illumina常规交易涨5.09%，推出全基因组癌症残留疾病检测工作流程","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ILMN":1},"content_text":"On May 29, Illumina rose 5.09% in regular trading, trading at $157.87/share, with trading volume of $142 million. The move was driven by the company's announcement of its first distributed whole-genome sequencing solution for high-sensitivity molecular residual disease (MRD) research.The new workflow is designed to support residual disease detection and cancer genomic profiling using solid tumor and blood samples. According to the company, the workflow completes processing in approximately five days and targets analytical sensitivity down to 10 parts per million for certain tumors. Illumina's Dragen analysis software links tumor profiles with circulating tumor DNA data and achieved 99.5% analytical specificity in testing designed to distinguish tumor signals from background noise. The company has opened early access to select clinical research partners and plans a broader commercial launch next year.The broader Life Sciences Tools & Services sector also posted strong gains, with Agilent up 18.83%, Icon PLC up 14.86%, Tempus AI up 8.54%, Thermo Fisher Scientific up 6.69%, and Danaher up 3.97%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1197222612","isCrawlerRequest":true}